6 quiz questions available for this topicTake Quiz

Conduct disorders in children and young people

SNOMED: 224120001886 wordsUpdated 03/03/2026
💡

Exam Tips

  • Diagnosis requires a persistent pattern with functional impairment across settings; one-off criminal/antisocial acts are insufficient.
  • In OSCE stations, always obtain collateral history from caregivers and school, and assess safeguarding risk explicitly.
  • Differentiate oppositional defiant disorder (defiant/irritable pattern) from conduct-dissocial disorder (rights violations, aggression, theft, serious rule-breaking).
  • State that psychosocial interventions are first-line; medication is adjunctive and specialist-led, not routine.
  • High-yield prognostic point: onset before age 10 years and comorbid ADHD predict worse long-term outcomes.

Definition

Conduct disorder is a persistent pattern of dissocial, aggressive, or markedly defiant behaviour in a child or young person that repeatedly breaches age-appropriate social expectations, rules, or the rights of others across settings. It is diagnosed clinically when behaviours are recurrent, prolonged, and associated with functional impairment at home, school, and with peers, rather than isolated incidents of misbehaviour.

Pathophysiology

The disorder is best understood as a biopsychosocial condition rather than a single-lesion disease. Vulnerability appears to arise from interaction between genetic liability (including heritable externalising traits), neurodevelopmental factors (impaired executive control, reward sensitivity, emotional dysregulation, and in some children callous-unemotional traits), and environmental exposures such as harsh/inconsistent parenting, trauma, domestic conflict, deprivation, and deviant peer reinforcement. Developmental pathways differ: early-onset presentations are more strongly linked to neurodevelopmental comorbidity (especially ADHD), entrenched coercive parent-child cycles, and poorer long-term outcomes, while adolescent-onset cases more often remit in early adulthood. For revision diagrams, review the coercion-cycle model and developmental trajectory charts commonly shown in child psychiatry textbook figures on disruptive behaviour disorders.

Risk Factors

  • Male sex
  • Special educational needs or learning difficulties
  • Comorbid mental health disorders, especially ADHD
  • Family history of conduct disorder or antisocial behaviour
  • Parental mental illness, substance misuse, or criminality
  • Harsh, inconsistent, neglectful, or low-warmth parenting
  • Physical or sexual abuse, bullying, and other trauma exposures
  • Frequent caregiver changes, institutional care, or being looked after
  • Domestic violence and high parental conflict
  • Socioeconomic deprivation and low household income
  • Maternal smoking during pregnancy
  • Association with antisocial peer groups and substance misuse

Clinical Features

Symptoms

  • Persistent defiance, disobedience, argumentative or provocative behaviour
  • Frequent severe temper outbursts and anger/irritability
  • Aggression towards peers, adults, or animals
  • Deceitfulness, repeated lying, or stealing
  • Serious rule violations (truancy, running away, staying out at night without permission)
  • Deliberate property damage, vandalism, or fire-setting
  • Functional deterioration in school attainment, family relationships, and peer relationships

Signs

  • Observed pattern of antisocial behaviour across multiple settings (home, school, community)
  • Bullying, physical fights, intimidation, or coercive interpersonal style
  • Cruelty to people/animals or reduced empathy in some presentations
  • Persistent school behavioural sanctions, exclusions, or repeated disciplinary incidents
  • Collateral reports from caregivers/teachers confirming chronicity (>=6-12 months depending on subtype)
  • Evidence of associated risks: self-harm, substance use, offending, or safeguarding concerns

Investigations

Comprehensive clinical psychiatric assessment (child + caregiver + school collateral):Persistent, impairing antisocial/defiant pattern across settings; supports ICD-11 disruptive behaviour/dissocial diagnosis
Risk and safeguarding assessment:Identifies immediate risk to self/others, abuse/neglect exposure, and need for urgent safeguarding action
Screening for comorbidity (ADHD, autism, depression, anxiety, PTSD, substance misuse, learning disability):Comorbid conditions frequently present and alter treatment plan and prognosis
Functional assessment (school attendance/attainment, peer and family functioning):Documents impairment severity and baseline for response monitoring
Baseline physical health checks before antipsychotic use (weight/BMI, BP, pulse, glucose/HbA1c, lipids, prolactin, movement-disorder review):May reveal metabolic or endocrine risk factors and provides safety baseline for treatment monitoring

Management

Lifestyle Modifications

  • Offer structured parent-training/parenting programmes as first-line for younger children and many school-age presentations
  • Use child-focused psychological work (problem-solving skills, emotion regulation, anger management) when developmentally appropriate
  • Deliver family and multi-agency interventions (school, social care, youth services); consider multisystemic approaches in severe cases
  • Address environmental drivers: bullying, domestic abuse exposure, parental mental health/substance misuse, and school support needs
  • Create a clear risk-management and safeguarding plan when violence, abuse, exploitation, or serious offending risk is present

Pharmacological Treatment

Atypical antipsychotic (specialist-only, adjunctive, short term)

  • Risperidone oral: age 5-17 years, start 250 micrograms once daily if <50 kg or 500 micrograms once daily if >=50 kg; adjust every other day in 250-500 microgram steps; usual 500 micrograms once daily (<50 kg) or 1 mg once daily (>=50 kg); max 750 micrograms daily (<50 kg) or 1.5 mg daily (>=50 kg); licensed short-term use (up to 6 weeks) for persistent aggression in conduct disorder with subaverage intellectual functioning

Do not use medication as routine first-line treatment for conduct disorder. Reserve risperidone for severe aggression/emotional dysregulation after psychosocial treatment failure and under specialist child psychiatry supervision. Monitor weight/metabolic profile, extrapyramidal effects, prolactin-related effects, sedation, and cardiovascular risk; use lowest effective dose for shortest duration.

Medication for comorbid ADHD (when diagnostic criteria met)

  • Methylphenidate immediate-release: typically start 5 mg once or twice daily, titrate at weekly intervals according to response/tolerability
  • Lisdexamfetamine: typically start 30 mg once daily in the morning, then titrate
  • Atomoxetine: weight-based daily dosing in children/adolescents if stimulants are unsuitable or ineffective

Treating comorbid ADHD can improve behaviour and long-term outcomes. Observe ADHD prescribing cautions: cardiovascular history/examination, appetite/weight suppression, sleep disturbance, misuse/diversion risk with stimulants, and suicidality warning with atomoxetine.

Complications

  • Progression to persistent antisocial behaviour and criminal offending
  • Development of antisocial personality disorder in adulthood (risk markedly higher in early-onset severe cases)
  • Substance and alcohol misuse disorders
  • Depression, anxiety, self-harm, and increased suicide risk
  • Educational failure, truancy, exclusions, and early school leaving
  • Unemployment, low income, and unstable adult relationships
  • Family breakdown and safeguarding involvement

Prognosis

Outcome is heterogeneous and strongly influenced by age at onset and comorbidity. Adolescent-onset cases often improve, with many stopping antisocial behaviour by early adulthood, whereas early-onset and severe multi-setting presentations have a higher risk of persistent psychiatric, social, educational, and forensic problems. Prognosis worsens with callous-unemotional traits, ADHD/hyperactivity, lower cognitive ability, high family adversity, and ineffective schooling, and improves with early identification, evidence-based parenting interventions, appropriate educational support, and active treatment of comorbid ADHD.

Sources & References

💊BNF Drug References(1)

NICE Guidelines(1)

📖Textbook References(20)

  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1342)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1551)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1499)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1641)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1736)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1259)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 745)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 745)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1730)[context]
  • Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 336)[context]
  • _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 2553, 2554)[context]
  • _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 2532)[context]
  • _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 3082, 3083)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1274)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1079, 1080)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1080)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 189)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 359, 360)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 720)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1218)[context]

Test Your Knowledge

6 quiz questions available for this topic

Start Quiz